We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KMTS, Biobeat Partner to Expand Diagnostic Insight in Cardiac Recovery
Read MoreHide Full Article
Key Takeaways
KMTS announced a collaboration with Biobeat, including an exclusive license and a $5M Series B investment.
KMTS integrates FDA-cleared cuffless blood pressure monitoring into the ASSURE WCD for at-home recovery.
Per Kestra, ACE-PAS data reflects 72% hypertensive patients, highlighting BP challenges post-cardiac events.
Kestra Medical Technologies, Ltd.(KMTS - Free Report) announced a collaboration with Biobeat Technologies, Ltd. to improve patient monitoring and diagnosis insights for people who rely on the ASSURE Wearable Cardioverter Defibrillator (WCD) during cardiac recovery. The two companies will work together to develop the latest technology and share an exclusive licensing agreement. As part of the deal, Kestra will also invest $5 million in Biobeat’s Series B financing.
Per management, the collaboration is designed to improve decision-making by clinicians with the help of enhanced blood pressure visibility during a critical cardiac recovery phase. The partnership aims to provide digital healthcare insights while patients recover and strengthen the ASSURE system as a flexible platform that supports remote, at-home care.
KMTS Stock’s Trend Following the News
Following the announcement, shares of Kestra declined 5.9% at yesterday’s closing. Over the past six months, the stock has climbed 42.8% compared with the industry’s 0.8% growth and the S&P 500’s 14.4% rise.
In the long run, by integrating Biobeat’s FDA-cleared blood pressure monitoring technology into the ASSURE WCD platform, Kestra enhances the clinical relevance of the ASSURE system as a connected, data-driven cardiovascular care platform for better care of patients with complex heart conditions. The partnership reinforces Kestra’s positioning and supports deeper clinician adoption and sustained growth in at-home cardiac monitoring solutions.
KMTS currently has a market capitalization of $1.37 billion.
Image Source: Zacks Investment Research
More on the Collaboration
Biobeat’s patch-based wearable cuffless ambulatory blood pressure monitoring device is the only FDA-cleared device that uses photoplethysmography-based sensor technology to provide continuous blood pressure measurements over 24 hours while patients recover at home. Kestra plans to add this capability to its ASSURE Wearable Cardioverter Defibrillator to deliver comprehensive data insights.
The collaboration is supported by data from Kestra’s ASSURE Wearable Cardioverter Defibrillator Clinical Evaluation Post-Approval Study (ACE-PAS), the largest real-world evaluation of wearable defibrillators to date. With 72% of patients identified as hypertensive, the study underscores the challenges of managing blood pressure during cardiac recovery as patients undergo guideline-directed medical therapy.
The agreement also enhances Kestra’s ASSURE platform’s flexibility and scalability, capable of supporting clinical needs in outpatient cardiac care. The equity investment further provides Kestra with early exposure to differentiated monitoring technology that could support product extensions. Over time, the collaboration may strengthen Kestra’s competitive position by deepening clinical utility and reinforcing its role as a long-term partner in cardiac recovery management.
Industry Prospects Favoring Market
Going by data provided by Precedence Research, the wearable medical devices market is valued at $67.65 billion in 2026 and is expected to witness a CAGR of 25.1% through 2035. Factors like the rising demand for remote patient monitoring devices, along with home healthcare solutions and rising consumer focus toward fitness for leading a healthy lifestyle, influence market growth for wearable medical devices.
Other News
Kestra aims to expand its sales team, sharing positive results from the post-approval study at the American Heart Association meeting. The company is strengthening its finances through the recent equity offering of 6,000,000 common shares at $23.00 per share, raising about $138 million before expenses and gave underwriters the option to buy up to 900,000 additional shares.
The company stays focused on growing the wearable defibrillator market and continuing to meet the needs of patients and the doctors who prescribe its products.
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , AtriCure (ATRC - Free Report) and Boston Scientific (BSX - Free Report) .
Phibro Animal Health, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.7%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%. You can see the complete list of today’s Zacks #1 Rankstocks here.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.77%.
AtriCure, currently flaunting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 adjusted loss per share of 1 cent, 90.9% narrower than the Zacks Consensus Estimate. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%.
ATRC has an estimated earnings growth rate of 64.2% for 2025 compared with the industry’s 12.7% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.06%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion beat the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.9% growth. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
KMTS, Biobeat Partner to Expand Diagnostic Insight in Cardiac Recovery
Key Takeaways
Kestra Medical Technologies, Ltd.(KMTS - Free Report) announced a collaboration with Biobeat Technologies, Ltd. to improve patient monitoring and diagnosis insights for people who rely on the ASSURE Wearable Cardioverter Defibrillator (WCD) during cardiac recovery. The two companies will work together to develop the latest technology and share an exclusive licensing agreement. As part of the deal, Kestra will also invest $5 million in Biobeat’s Series B financing.
Per management, the collaboration is designed to improve decision-making by clinicians with the help of enhanced blood pressure visibility during a critical cardiac recovery phase. The partnership aims to provide digital healthcare insights while patients recover and strengthen the ASSURE system as a flexible platform that supports remote, at-home care.
KMTS Stock’s Trend Following the News
Following the announcement, shares of Kestra declined 5.9% at yesterday’s closing. Over the past six months, the stock has climbed 42.8% compared with the industry’s 0.8% growth and the S&P 500’s 14.4% rise.
In the long run, by integrating Biobeat’s FDA-cleared blood pressure monitoring technology into the ASSURE WCD platform, Kestra enhances the clinical relevance of the ASSURE system as a connected, data-driven cardiovascular care platform for better care of patients with complex heart conditions. The partnership reinforces Kestra’s positioning and supports deeper clinician adoption and sustained growth in at-home cardiac monitoring solutions.
KMTS currently has a market capitalization of $1.37 billion.
Image Source: Zacks Investment Research
More on the Collaboration
Biobeat’s patch-based wearable cuffless ambulatory blood pressure monitoring device is the only FDA-cleared device that uses photoplethysmography-based sensor technology to provide continuous blood pressure measurements over 24 hours while patients recover at home. Kestra plans to add this capability to its ASSURE Wearable Cardioverter Defibrillator to deliver comprehensive data insights.
The collaboration is supported by data from Kestra’s ASSURE Wearable Cardioverter Defibrillator Clinical Evaluation Post-Approval Study (ACE-PAS), the largest real-world evaluation of wearable defibrillators to date. With 72% of patients identified as hypertensive, the study underscores the challenges of managing blood pressure during cardiac recovery as patients undergo guideline-directed medical therapy.
The agreement also enhances Kestra’s ASSURE platform’s flexibility and scalability, capable of supporting clinical needs in outpatient cardiac care. The equity investment further provides Kestra with early exposure to differentiated monitoring technology that could support product extensions. Over time, the collaboration may strengthen Kestra’s competitive position by deepening clinical utility and reinforcing its role as a long-term partner in cardiac recovery management.
Industry Prospects Favoring Market
Going by data provided by Precedence Research, the wearable medical devices market is valued at $67.65 billion in 2026 and is expected to witness a CAGR of 25.1% through 2035. Factors like the rising demand for remote patient monitoring devices, along with home healthcare solutions and rising consumer focus toward fitness for leading a healthy lifestyle, influence market growth for wearable medical devices.
Other News
Kestra aims to expand its sales team, sharing positive results from the post-approval study at the American Heart Association meeting. The company is strengthening its finances through the recent equity offering of 6,000,000 common shares at $23.00 per share, raising about $138 million before expenses and gave underwriters the option to buy up to 900,000 additional shares.
The company stays focused on growing the wearable defibrillator market and continuing to meet the needs of patients and the doctors who prescribe its products.
Kestra Medical Technologies, Ltd. Price
Kestra Medical Technologies, Ltd. price | Kestra Medical Technologies, Ltd. Quote
KMTS’s Zacks Rank & Stocks to Consider
Currently, KMTS carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , AtriCure (ATRC - Free Report) and Boston Scientific (BSX - Free Report) .
Phibro Animal Health, sporting a Zacks Rank #1 (Strong Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.7%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%. You can see the complete list of today’s Zacks #1 Rankstocks here.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.77%.
AtriCure, currently flaunting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 adjusted loss per share of 1 cent, 90.9% narrower than the Zacks Consensus Estimate. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%.
ATRC has an estimated earnings growth rate of 64.2% for 2025 compared with the industry’s 12.7% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.06%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion beat the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.9% growth. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 7.36%.